🇺🇸 FDA
Pipeline program

Finerenone (BAY94-8862)

17530

Phase 3 small_molecule completed

Quick answer

Finerenone (BAY94-8862) for Diabetic Kidney Disease is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer HealthCare AG
Indication
Diabetic Kidney Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials